An Introduction to Macular Degeneration
The treatment landscape for macular degeneration is evolving with many new potential therapies under investigation. The standard of care in wet age-related macular degeneration (AMD) was revolutionised in 2005 with the introduction of anti-VEGF therapies, and current research into port delivery systems and drug combinations aim to provide longer-lasting treatments. Dry AMD is a challenging condition with no current treatment option, but research into stem cell therapies and drugs that slow the progression of geographic atrophy show much promise.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Macular Degeneration Content
Can we improve the nAMD patient experience without compromising outcomes?
Watch leading experts discussing the multifactorial nature of nAMD, the efficacy ceiling and burden of current treatments.
Update on Avacincaptad Pegol for Geographic Atrophy
touchREVIEWS in Ophthalmology. 2022;16(1):Online ahead of journal publication.
Age-related macular degeneration (AMD) is characterized by age-associated thinning of the macula and formation of drusen. It has substantial global prevalence, especially in the older population, and it is the primary cause of permanent loss of vision in individuals 50 years and older in developd countries.1 Degeneration in the early and intermediate stages is known as […]
Carl Regillo, Hawaiian Eye 2022: Emerging Therapies for Wet Age-related Macular Degeneration
There are new treatment options for patients with wet age-related macular degeneration emerging, according to a presentation at Hawaiian Eye 2022. It was a pleasure to speak with Dr Carl Regillo (Thomas Jefferson University, Philadelphia, PA, USA) about his views on the latest treatments to emerge for wet age-related macular degeneration. The abstract entitled Update […]
Carl Regillo, Hawaiian Eye 2022: Ranibizumab Injection for the Treatment of Wet Age-related Macular Degeneration
A new ranibizumab injection offers hope for patients with wet age-related macular degeneration, according to a presentation at Hawaiian Eye 2022. It was great to catch up with Dr Carl Regillo (Thomas Jefferson University, Philadelphia, PA, USA), who talked to us about the ranibizumab injection and its advantages over anti-vascular endothelial growth factor injections. The […]
Ranibizumab and Neovascular Age-related Macular Degeneration
touchREVIEWS in Ophthalmology. 2021;15(2): 55-57 DOI: https://doi.org/10.17925/USOR.2021.15.2.55
The development of anti-vascular endothelial growth factor (VEGF) agents as intravitreal treatments for neovascular age-related macular degeneration (nAMD) has drastically improved the vision outcomes for this disorder. Ranibizumab, a recombinant, humanized monoclonal antibody that targets VEGF-A, was approved in 2006 by the US Food and Drug Administration (FDA) for the treatment of nAMD. The pivotal […]
Kyoko Ohno-Matsui, EURETINA 2021: Advantages and Limitations of a Deep Learning Algorithm
We were delighted to speak with Kyoko Ohno-Matsui (Tokyo Medical and Dental University, Tokyo, Japan) about the potential advantages and limitations of a deep learning algorithm for automated detection of myopic maculopathy and pathologic myopia in fundus images, and the challenges in developing this algorithm. Questions What are the potential advantages and limitations of a […]
Kyoko Ohno-Matsui, EURETINA 2021: Results of a Study Evaluating a Deep Learning Algorithm
It was a pleasure to catch up with Kyoko Ohno-Matsui (Tokyo Medical and Dental University, Tokyo, Japan), who discussed the results of her study evaluating a deep learning algorithm for automated detection of myopic maculopathy and pathologic myopia in fundus images. Questions What were the methodology and outcome measures of your study evaluating a deep […]
Faricimab: An Emerging Therapy for the Treatment of Neovascular Age-related Macular Degeneration
touchREVIEWS in Ophthalmology. 2021; 15(1):23–5 DOI: https://doi.org/10.17925/OPHT.2021.15.1.23
Neovascular age-related macular degeneration (nAMD) is characterized by the growth of abnormal blood vessels extending through Bruchs membrane in the macular region.1 This macular neovascularization (MNV) can be classified based on localization as either type 1, type 2, type 3 or mixed lesions.2 In type 1 MNV (also known as occult lesions), the neovascularization arises […]
Carl Regillo, Hawaiian Eye and Retina 2021: Geographic Atrophy – Current Therapeutic Approaches and Future Prospects
It was a pleasure to catch up with Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA), who talked us through the therapeutic approaches currently in clinical trial investigation for the treatment of geographic atrophy, and his views on exciting future prospects for treatment. Questions Could you give us a brief overview of the therapeutic approaches […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!